Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis

Completed · Phase 3 · Has a placebo group

Conditions studied: Psoriatic Arthritis

In brief

The purpose of this study was to provide up to 52 weeks of efficacy, safety and tolerability data to support registration of intravenous (i.v.) secukinumab (Initial dose of 6 mg/kg at Baseline (BSL) followed thereafter with 3 mg/kg administered every four weeks) in patients with active psoriatic arthritis (PsA) despite current or previous Non-steroidal anti-inflammatory drugs (NSAIDs), Disease-modifying antirheumatic drugs (DMARDs) and/or anti-tumor necrosis factor (TNF) therapy.

Key facts

Study ID

NCT04209205

Run by

Novartis Pharmaceuticals

People needed

381

Starts

2020-01-29

Expected to finish

2022-05-17

Last updated by the study team

2025-05-16

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Novartis Investigative Site — Fountain Valley, California, United States
• Novartis Investigative Site — Fullerton, California, United States
• Novartis Investigative Site — La Mesa, California, United States
• Novartis Investigative Site — Santa Monica, California, United States
• Novartis Investigative Site — Upland, California, United States
• Novartis Investigative Site — Van Nuys, California, United States
• Novartis Investigative Site — West Hills, California, United States
• Novartis Investigative Site — Denver, Colorado, United States
• Novartis Investigative Site — Clearwater, Florida, United States
• Novartis Investigative Site — Miami, Florida, United States
• Novartis Investigative Site — Ocoee, Florida, United States
• Novartis Investigative Site — Plantation, Florida, United States
• Novartis Investigative Site — Tampa, Florida, United States
• Novartis Investigative Site — Winter Park, Florida, United States
• Novartis Investigative Site — Marietta, Georgia, United States
• Novartis Investigative Site — Indianapolis, Indiana, United States
• Novartis Investigative Site — Bowling Green, Kentucky, United States
• Novartis Investigative Site — St Louis, Missouri, United States
• Novartis Investigative Site — Lincoln, Nebraska, United States
• Novartis Investigative Site — Voorhees Township, New Jersey, United States
• Novartis Investigative Site — Rochester, New York, United States
• Novartis Investigative Site — Greensboro, North Carolina, United States
• Novartis Investigative Site — Middleburg Heights, Ohio, United States
• Novartis Investigative Site — Oklahoma City, Oklahoma, United States
• Novartis Investigative Site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.